IPF Expert Roundtable Discussion Credit Submission Form

Complete and submit this form to apply for 0.5 AMA PRA Category 1 Credit™. Upon acceptance of this activity by The France Foundation, you will receive a certificate documenting your successful completion of this activity. Please note that this entire form must be completed to receive credit.

* = required fields
Participant Information
*First Name: *Last Name:
*Please indicate your degree(s): MD DO PharmD APRN PA Other:
*Address: Address 2:
*City: *State: *ZIP:
*Phone: *E-mail:
*Clinician type: Pulmonologist Pathologist Radiologist Primary Care Physician Other:
*Number of years in practice: <5 6-10 11-15 16-20 21-25 > 25
*Percent of patients with IPF in your practice:
*May we contact you in the future with a brief survey to assess how you have used the information presented in this activity or to assess other educational needs? Yes No

*Indicate the number of AMA PRA Category 1 Credits™ you are claiming (May not exceed 0.5 credit)

Met Learning Objectives:
4 – Strongly Agree   3 – Agree   2 – Disagree   1 – Strongly Disagree
Upon completion of this activity, I will be able to:
Describe recent progress in diagnosing IPF comorbid conditions, including pulmonary arterial hypertension (PAH) 4 3 2 1
Describe recent clinical trial results on IPF therapies and incorporate this information into the management 4 3 2 1
Enduring Material
Please rate the overall content in this activity: Too Basic Appropriate Too Complex
Bias, Fair Balance:
Was this activity fair, balanced, objective, and free from commercial bias? Yes No
If no, please state reason(s):
Practical Application:
4 – Strongly Agree   3 – Agree   2 – Disagree   1 – Strongly Disagree
I felt that the format used in this activity was a beneficial method of learning 4 3 2 1
What I learned in this activity will improve my ability to care for my patients with IPF 4 3 2 1
List one thing you would do differently or incorporate into your clinical practice as a consequence of this educational activity.
Barriers
What are the top 3 barriers you feel might inhibit your ability to incorporate any of the above changes into your clinical practice?
Ongoing Unmet Educational Needs
Recommendations for future CME topics in this disease area:
How Did You Come to Participate in this CME Activity?
Direct Mail Colleague Web Search Conference Display E-mail Advertisement
Have You Participated in a PILOT™ CME Activity in the Past? Yes No
If yes, what is the approximate number of activities that you have participated in this calendar year?
1-3 4-6 7-9 > 10
If no, after participating in this activity, how likely are you to participate in a PILOT CME activity in the future?
Very Likely Likely Unlikely Unsure
Posttest
1. Pulmonary hypertension is best assessed by
Right heart catheterization
Echocardiography
Echocardiography plus BNP
HRCT
No method is dependable
2. Bosentan treatment of IPF patients was associated with an increase in 6MWT distance. This result is being verified in the BUILD 3 trial.
True
False
3. The INSPIRE trial was halted at a prespecified interim analysis point because of lack of benefit of IFNγ-1b.
True
False
4. Which condition is a comorbidity of IPF?
Pulmonary hypertension
GERD
Cough
Dyspnea
All of the above
5. Approximately what proportion of IPF patients have pulmonary hypertension at the time of lung transplantation?
< 10%
30%
55%
85%
 
 
 
 

 

 

Privacy   |   Terms of Use   |   Contact Us

Welcome   |   What is PILOT™?   |   What is IPF?   |   Steering Committee   |   CME - Point of Care
CME Event Calendar   |   CME - Online Activities   |   CME Interactive Cases   |   CME Peer-to-Peer Dialogue
Image Library   |   Reading Room   |   Patient Counseling Tools   |   IPF Resource Archives   |   Useful Links